Biotechnology

Viracta Therapeutics

Viracta Therapeutics Announces Layoffs and Cessation of Operations

Viracta Therapeutics Evaluates Strategic Options to Address Virus-Related Cancers

Viracta Therapeutics Announces Exploration of Strategic Options

Rodman & Renshaw Downgrades Viracta Therapeutics (VIRX.US) Rating to Neutral, Target Price Reduced to $0.25

Viracta Therapeutics released FY2024 Q3 earnings on November 13 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.2666 USD (forecast -0.245 USD)

Viracta Therapeutics released FY2024 Cumulative Q3 Earnings on November 13, 2024 (EST), with Revenue at 0 and EPS at -0.7485

Viracta Therapeutics: Layoffs of approximately 23%

Viracta Therapeutics Announces Positive Results from NAVAL-1 Trial Phase 1

Viracta Therapeutics released FY2023 Cumulative 3Q Earnings on November 9, 2023 (EST), with Revenue at 0 and EPS at -0.9694

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

VTRS

VIRX

IBBQ

Shares of Viatris Inc. (VTRS) fell 1.27% to $17.17 on Friday, underperforming the overall positive market, with the S&P 500 rising 0.84%. This decline ended a five-day winning streak for the stock, which is now 1.60% below its 52-week high of $17.45 reached on May 7th. Trading volume was 19.5 million, surpassing the 50-day average of 11.3 million.

MarketWatch Automated

Viatris

VG Health

iShares Global Healthcare

Health Care Select Sector SPDR

iShares Biotechnology ETF

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

S&P 500

Dow Jones Industrial Average

Viatris Inc. Stock Falls Friday, Underperforms Market

LABU

SBIO

Bioventix CFO Increases Personal Stake with Share Purchase

Tip Ranks

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Bioventus

First Trust NYSE Arca Biotech Index Fd

Bioventix CFO Increases Personal Stake with Share Purchase

MXRX

ValiRx updates registered office as it advances oncology and women’s health focus

MED-X, INC.

ValiRx updates registered office as it advances oncology and women’s health focus

ARKG

On March 30, 2026, a biotechnology company named Centivax, Inc. based in South San Francisco completed a funding round that exceeded expectations by securing $37 million. The company focuses on developing vaccines and therapies aimed at providing long-lasting and universal defense against a wide range of targets.

Unusual Whales

Ark Genomic Revolution ETF

VBI VACCINES INC CDA

Centivax Closes $37 Million Financing to Accelerate Phase 2 Clinical Development of Universal Flu and Advance Follow-On Portfolio to Clinical Readiness

ValiRx trims costs and expands oncology pipeline with new human and veterinary initiatives

ValiRx trims costs and expands oncology pipeline with new human and veterinary initiatives

A company in San Diego, Virewirx, has received a Phase II Small Business Innovation Research (SBIR) OUSW (R&E) FutureG contract worth $1.9 million from the Office of the Under Secretary of War (OUSW). The contract is for the development of an advanced 5G system capable of operating effectively in difficult Radio Frequency (RF) conditions. This innovative technology aims to facilitate crucial communications in environments where it was previously challenging, ensuring that military personnel can maintain connectivity for coordination and safety during missions.

Comm Servcies Select Sector SPDR

Virewirx awarded $1.9M SBIR contract to develop advanced 5G system for OUSW to ensure mission-critical communications.

Virion Therapeutics announced at CROI 2026 that its novel immunotherapy, VRON-0200, demonstrated broad and sustained anti-HBV immunity in most chronically infected patients after a single dose. The treatment showed significant HBsAg declines lasting up to 360 days and maintained a favorable safety profile. The company aims to develop VRON-0200 as a foundational agent in future HBV treatment strategies, potentially reducing the need for rescue medications. A Phase 2b trial is planned to further evaluate its efficacy in combination with antiviral therapies.

MorningStar

Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026

On December 26, 2024, a company called Viracta Therapeutics, Inc. (Nasdaq: VIRX), located in San Diego, revealed plans to evaluate various strategic alternatives. This clinical-stage precision oncology firm specializes in handling virus-related cancers affecting patients globally. The Board of Directors is spearheading this initiative to explore multiple options for the company's future direction and growth.

Viracta Therapeutics closes NAVAL-1 trial and explores strategic options; Board of Directors initiates process to explore alternatives.

SAN DIEGO, Feb. 05, 2025 ( GLOBE NEWSWIRE ) -- Viracta Therapeutics, Inc. ( Nasdaq: VIRX ) , a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its ...

GlobeNewswire

Viracta Therapeutics Announces Wind Down of Operations

Viracta Therapeutics(VIRX.US)

Viatris Inc. Stock Falls Friday, Underperforms Market

Bioventix CFO Increases Personal Stake with Share Purchase

ValiRx updates registered office as it advances oncology and women’s health focus

Centivax Closes $37 Million Financing to Accelerate Phase 2 Clinical Development of Universal Flu and Advance Follow-On Portfolio to Clinical Readiness

ValiRx trims costs and expands oncology pipeline with new human and veterinary initiatives

Virewirx awarded $1.9M SBIR contract to develop advanced 5G system for OUSW to ensure mission-critical communications.

Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026

Viracta Therapeutics closes NAVAL-1 trial and explores strategic options; Board of Directors initiates process to explore alternatives.

Viracta Therapeutics Announces Wind Down of Operations